However, no EGFR TKI has been approved for NSCLC patients harboring insertion mutations in <i>EGFR</i> exon 20 (<i>EGFR</i>ex20ins), a subgroup of uncommon <i>EGFR</i> mutations resistant to first-generation EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.